钙卫蛋白及抗中性粒细胞胞浆抗体联合检测对炎症性肠病的诊断价值研究

摘要

目的 探讨钙卫蛋白与抗中性粒细胞胞浆抗体(ANCA)联合检测对炎症性肠病(IBD)的诊断价值.方法 收集确诊为IBD的患者79例作为IBD组,腹痛、腹泻等排除IBD的患者42例作为疾病对照组,健康体检者34例作为健康对照组.分别检测血液样本中ANCA和粪便样本中钙卫蛋白的水平.结果 79例IBD患者粪便钙卫蛋白浓度为(493.86±204.18)μg/g高于疾病对照组[(71.46±60.51)μg/g]和健康对照组[(36.19±13.46)μg/g].钙卫蛋白在IBD组、疾病对照组和健康对照组中的阳性率分别为57.0%、19.0%、0.0%;ANCA在三组中的阳性率分别为63.3%、4.8%、0.0%.IBD组的钙卫蛋白、ANCA阳性率显著高于其他两组(P＜0.05).钙卫蛋白与ANCA联合检测在IBD组、疾病对照组和健康对照组中的阳性率分别为78.5%、23.8%和0.0%.结论 钙卫蛋白和ANCA联合检测可显著提高IBD的诊断率,为临床IBD的早期诊断和治疗提供可靠依据.%Objective To explore the diagnostic value of combined detection of calprotectin and antineutrophil cytoplasniic anti bodies(ANCA) in inflammatory bowel disease(IBD). Methods 79 patients with definite diagnosis of IBD(IBD group) ,42 patients with abdominal pain and diarrhea,but without IBD(disease control group) and 34 cases of healthy subjects(healthy control group) were enrolled,and detected for ANCA level in blood sample and calprotectin level in and fecal sample. Results The fecal calprotec tin concentration was (493. 86 + 204. 18) μg/g in IBD group, higher than (71. 46+60. 51) and (36. 19 + 13. 46) μg/g in disease control group and healthy control group, respectively. The positive rates of calprotectin in IBD group, disease control group and healthy control group were 57. 0% ,19. 0% and 0. 0%,of ANCA in the three groups were 63. 3%,4. 8% and 0. 0%. The positive rates of calprotectin and ANCA in IBD group were higher than those in the other two groups(P<0. 05). The positive rates of com bined detection of calprotectin and ANCA in IBD group,disease control group and healthy control group were 78. 5% ,23. 8% and 0. 0%. Conclusion Combined detection of calprotectin and ANCA could significantly improve the diagnostic rate of IBD,and could provide evidence for early diagnosis and treatment of IBD.